Entering text into the input field will update the search result below

Seattle Genetics teams up with Unum Therapeutics in cancer therapies

Jun. 08, 2015 10:30 AM ETSeagen Inc. (SGEN) StockSGENBy: Douglas W. House, SA News Editor
  • Seattle Genetics (SGEN) enters into a collaboration with privately-held Unum Therapeutics to develop and commercialize novel antibody-coupled T cell receptor (ACTR) therapies for cancer. The partnership will leverage Unum's proprietary ACTR technology, which enables programming of a patient's T cells to attack tumor cells when co-administered with tumor-specific therapeutic antibodies, with SGEN's large portfolio of cancer targets and tumor-specific monoclonal antibodies.
  • Under the terms of the agreement, SGEN will pay Unum an upfront fee of $25M and invest $5M in Unum's next round of financing. The companies will initially develop two ACTR products with SGEN having an option to add a third. Unum will be responsible for preclinical research and clinical development through Phase 1, funded by SGEN. The firms will co-develop and jointly fund post-Phase 1 programs unless either opts out. They will co-commercialize and share profits on an equal (50/50) basis in the U.S. SGEN will have exclusive commercial rights ex-U.S. and will pay Unum high-single- to mid-double digit royalties. Unum will be eligible to receive up to $615M in option fees and milestones across the three ACTR programs.
  • On the basis of this deal, SGEN will provide revised 2015 financial guidance with its Q2 results, currently planned for July 30.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
SGEN--
Seagen Inc.